Starting or Strengthening a Drug Bulletin - A Practical Manual
(2005; 165 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentHow the manual was produced
View the documentAbout ISDB
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Rational use of medicines
Open this folder and view contents3. What are drug bulletins?
Open this folder and view contents4. Defining aims, target and type of bulletin
Open this folder and view contents5. Planning resources
Open this folder and view contents6. Planning bulletin production: schedules and timing
Open this folder and view contents7. The editorial process
Open this folder and view contents8. Reviewing a new drug: is it a therapeutic advance?
Open this folder and view contentsAnnexe to Chapter 8: Evaluating harm
Open this folder and view contents9. Design and production
Open this folder and view contents10. Dissemination
Open this folder and view contents11. Organizational and legal issues
Open this folder and view contents12. Evaluating quality and usefulness
Open this folder and view contents13. Partnership and collaboration
Open this folder and view contents14. Keeping records and creating a memory
Close this folderAppendix: Electronic sources of information
View the documentFor general access to evidence
View the documentJournal articles
View the documentSystematic reviews
View the documentNational disease prevention and control, health promotion etc.
View the documentHealth technology assessment
View the documentClinical guidelines
View the documentFormularies/Essential medicines
View the documentRegulatory authorities
View the documentAdverse effects
View the documentInformation about/for patients
View the documentDrug promotion
View the documentNetworks and directories
View the documentISDB member bulletins
View the documentFeedback and evaluation form
 

Adverse effects

Australian Adverse Drug Reactions Bulletin

The Australian Adverse Drug Reactions Bulletin is produced six times a year by the Adverse Drug Reactions Advisory Committee (ADRAC), a subcommittee of the Australian Drug Evaluation Committee which advises the Therapeutic Goods Administration on the safety of medicines.
http://www.tga.gov.au/adr/aadrb.htm


Current problems

Articles and alerts from the UK medicines regulatory agency.
http://www.medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htmCSM


Canadian Adverse Drug Reaction Newsletter

From Health Canada.
http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adrindex_e.html


U.S. Food and Drug Administration Medwatch Safety Information and Adverse Event Reporting Program

Medwatch provides safety information on the drugs and other medical products regulated by the U.S. Food and Drug Administration.
http://www.fda.gov/medwatch/


Institute for Safe Medication Practices, USA

The Institute for Safe Medication Practices (ISMP) is a non-profit organization that works closely with healthcare practitioners and institutions, regulatory agencies, professional organizations and the pharmaceutical industry to provide education about adverse drug events and their prevention.
http://www.ismp.org/

WHO publications on pharmacovigilance

The Importance of Pharmacovigilance: safety monitoring of medicinal products, 2002, World Health Organization.
http://www.who.int/medicines/library/qsm/ip_booklet.pdf


Safety of Medicines: a guide to detecting and reporting adverse drug reactions

http://www.who.int/medicines/library/qsm/who-edm-qsm-2002-2/esd_safety.pdf


Safety Monitoring of Medicinal Products: guidelines for setting up and running a pharmacovigilance centre.

http://www.who-umc.org/pdfs/guidelines.pdf


WHO Collaborating Centre for International Drug Monitoring. Uppsala, Sweden

http://www.who-umc.org/index2.html

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014